FDA to Review Mogamulizumab as Treatment for Cutaneous T-cell Lymphoma
News
The U.S. Food and Drug Administration (FDA) will review the use of mogamulizumab as a treatment for cutaneous T-cell lymphoma (CTCL) in patients who received at least one prior line of ... Read more